Navigation Links
Rx for Africa Ethiopia to Launch a Minimum of 36 New Products in 2009
Date:1/21/2009

Drugs for Malaria and HIV/AIDS a High Priority

ADDIS ABABA, Ethiopia, Jan. 21 /PRNewswire-FirstCall/ -- Rx for Africa, Inc.'s (Pink Sheets: RXAF.PK) wholly owned operating subsidiary, Rx Africa (Ethiopia) P.L.C. announced today that it's newly completed R&D center has formulated nine generic pharmaceuticals, and is on track to launch a minimum of 36 new products in calendar 2009. The state of the art malaria drug Artemisinin is scheduled for a third-quarter launch, and HIV/AIDS pharmaceuticals are in process. "Globally, malaria is responsible for more than one million deaths per year, with 90% of these deaths here in sub-Saharan Africa. Over 22 million Africans live with HIV/AIDS, and 1.5 million a year die from it," said Dr. Mulugetta Bezzabeh, the CEO of Rx for Africa, Inc. "The urgency of meeting such crucial health needs is why we are so diligent in working towards our production goals."

"Additionally, our launch list of generic pharmaceuticals includes many standard antibiotics, anti-fungals, anti-inflammatory and analgesic drugs that are taken for granted in the U.S. and developed world, but of which there are still extreme shortages in Ethiopia, and throughout Sub-Saharan Africa. Our staff in Ethiopia, including scientists from India and Germany, is now accomplishing this important work and meeting or exceeding scheduling milestones."

About Rx for Africa, Inc.

Rx for Africa, Inc. is a public New Jersey corporation, formed in 2007 to invest in companies manufacturing generic pharmaceuticals in Sub-Saharan Africa. Rx Africa (Ethiopia) P.L.C. is a wholly-owned operating subsidiary of Rx for Africa, Inc., with a campus just outside Addis Ababa, Ethiopia, comprising a factory, R&D center and office facilities, currently producing six generic pharmaceutical products. The company sells 100% of its current production through distributors. Shares of Rx for Africa, Inc. common stock are traded under the symbol RXAF.PK on the Pink Sheets.

For more information, visit Rx for Africa, Inc.'s website: http://rxforafrica.com

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners or others that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


'/>"/>
SOURCE Rx for Africa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. South African policy on adolescents rights to access condoms is causing confusion
2. African-Americans have worse prognosis at colorectal cancer diagnosis
3. Outdoor alcohol advertising and problem drinking among African-American women in NYC
4. UCSF-Tanzania get $7.5M from Gates Foundation for partnership to train African health workers
5. Good News in Africa: Beyond the headlines
6. African Americans to Reach Health Resolutions Through Search Your Heart
7. Gay and bisexual African-American men have the lowest use of prostate testing
8. Nothing But Nets Delivers 740,000 Bed Nets to Central African Republic
9. Birthing Project USA Unites to Reduce the African-American Infant Mortality Rate: Pilgrimage to Babyland
10. Church effort sharply increases first-time African-American blood donors
11. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 22, 2017 , ... Our high-octane society demands higher stands ... brain. , Power On, a mental performance enhancer from Modus Nutrition, provides scientifically ... capsule contains Cognizin® Citicoline, a branded form of the brain health nutrient citicoline ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... Fla. (PRWEB) , ... February 22, 2017 , ... ... is just as effective on smaller and sometimes harder to reach ones, according ... were presented at the International Stroke Conference in Houston by Ricardo A. Hanel, ...
(Date:2/22/2017)... Washington, D.C. (PRWEB) , ... February 22, 2017 ... ... is being celebrated throughout the country today, as organizations, advocates, and individuals join ... improve detection and treatment access to ultimately save lives. , “Today we mark ...
(Date:2/22/2017)... ... 22, 2017 , ... A product of digesting a micronutrient found in soy ... from eating soy foods, while others do not, a University of Pittsburgh Graduate School ... equol—a substance made by some types of “good” gut bacteria when they metabolize isoflavones ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Feb. 22, 2017  Allergan plc (NYSE: AGN), ... be a Gold sponsor of the Alzheimer,s Foundation ... Tour." This tour commemorates AFA,s15 years of educating ... and programs. The tour will include AFA,s free ... and displays of the AFA Quilt to Remember. ...
(Date:2/22/2017)... Oncternal Therapeutics, Inc., a clinical-stage biotechnology ... common malignancies, today announced the closing of an ... to use the proceeds to further clinical development ... preclinical development of a new ROR1-targeted antibody-drug conjugate ... anti-ROR1 monoclonal antibody being developed to treat patients ...
(Date:2/22/2017)... NEW YORK , February 22, 2017 ... half of the 50 states in the U.S. have now legalized ... Brazil , Canada , ... , Portugal , Uruguay ... steps to legalize or decriminalize cannabis in the last two years. ...
Breaking Medicine Technology: